Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad Pharmaceuticals Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.ariad.com

Latest From Ariad Pharmaceuticals Inc.

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A

News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.

Pricing Debate Drug Review

BIO 2019 Notebook: Sharpless On Pricing, Takeda M&A Strategy, FDA Cell And Gene Therapy Staffing

News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout; and CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates.

Pricing Debate M & A

Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018

The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.

China Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Paris Panayiotopoulos, Pres. & CEO
    Jennifer L Herron, EVP, Chief Commercial Officer
    Hugh M Cole, SVP & CBO
  • Contact Info
  • Ariad Pharmaceuticals Inc.
    Phone: (617) 494-0400
    26 Landsdowne St.
    Cambridge, MA 02139-4234
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register